BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Aerocrine: UK Clinical Study Demonstrates That Asthma Tests Can Identify Non-Adherence to Medication


12/17/2012 9:52:36 AM

SOLNA, Sweden--(BUSINESS WIRE)--Aerocrine AB (OMX Nordic Exchange: AERO) announces that a clinical trial published in The American Journal of Respiratory and Critical Care Medicine shows that FeNO-testing is an excellent tool to identify patients that don’t adhere to treatment. The American Journal of Respiratory and Critical Care Medicine published on December 1, 2012, the results of a clinical study done at Queen’s University in Belfast, Northern Ireland. The results show how fractional exhaled nitric oxide (FeNO) measurement is an excellent tool for identifying patients who did not use their prescribed inhaled corticosteroids, i.e. did not adhere to treatment. Identifying non-adherence to medication is important because it allows improved patient characterization and tailoring of asthma management to individual needs, which, in turn, results in better patient outcomes at lower cost. Aerocrine’s patented FeNO test, with the NIOX MINO® device, was used in the study. The UK study is entitled: The Utility of Fractional Exhaled Nitric Oxide Suppression in Identification of Nonadherence in Difficult Asthma; its purpose was to identify a test for non-adherence using fractional exhaled nitric oxide (FeNO) suppression after directly observed inhaled corticosteroid treatment. The study concluded that the FeNO suppression test can identify whether or not patients use their inhaled corticosteroid therapy properly and if patients, who fill their prescriptions, took their medicine. Non-adherence is common and ranges from 35–65%.

Read at BioSpace.com

Aerocrine
 
 
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES